- Home
- SLMBP vs MRK Comparison
SLMBP vs MRK Comparison
Compare SLMBP & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLMBP
- MRK
- Stock Information
- Founded
- SLMBP N/A
- MRK 2000
- Country
- SLMBP United States
- MRK United States
- Employees
- SLMBP 1710
- MRK N/A
- Industry
- SLMBP Finance: Consumer Services
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- SLMBP Finance
- MRK Health Care
- Exchange
- SLMBP Nasdaq
- MRK Nasdaq
- Market Cap
- SLMBP N/A
- MRK 218.2B
- IPO Year
- SLMBP N/A
- MRK N/A
- Fundamental
- Price
- SLMBP $75.00
- MRK $77.66
- Analyst Decision
- SLMBP
- MRK Buy
- Analyst Count
- SLMBP 0
- MRK 15
- Target Price
- SLMBP N/A
- MRK $115.93
- AVG Volume (30 Days)
- SLMBP N/A
- MRK 15.6M
- Earning Date
- SLMBP N/A
- MRK 04-24-2025
- Dividend Yield
- SLMBP N/A
- MRK 4.17%
- EPS Growth
- SLMBP N/A
- MRK 667.14
- EPS
- SLMBP N/A
- MRK 6.88
- Revenue
- SLMBP N/A
- MRK $63,922,000,000.00
- Revenue This Year
- SLMBP N/A
- MRK $2.31
- Revenue Next Year
- SLMBP N/A
- MRK $6.35
- P/E Ratio
- SLMBP N/A
- MRK $11.29
- Revenue Growth
- SLMBP N/A
- MRK 4.10
- 52 Week Low
- SLMBP N/A
- MRK $75.93
- 52 Week High
- SLMBP N/A
- MRK $134.63
- Technical
- Relative Strength Index (RSI)
- SLMBP 59.52
- MRK 36.06
- Support Level
- SLMBP $73.33
- MRK $78.29
- Resistance Level
- SLMBP $75.49
- MRK $84.71
- Average True Range (ATR)
- SLMBP 0.97
- MRK 2.30
- MACD
- SLMBP 0.33
- MRK 0.08
- Stochastic Oscillator
- SLMBP 91.07
- MRK 16.63
About SLMBP SLM Corporation Floating Rate Non-Cumulative Preferred Stock Series B
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.